Metallothionein 1 negatively regulates glucose-stimulated insulin secretion and is differentially expressed in conditions of beta cell compensation and failure in mice and humans
Mohammed Bensellam,Yan-Chuan Shi,Jeng Yie Chan,D. Ross Laybutt,Heeyoung Chae,Michel Abou-Samra,Evan G. Pappas,Helen E. Thomas,Patrick Gilon,Jean-Christophe Jonas
DOI: https://doi.org/10.1007/s00125-019-05008-3
IF: 8.2
2019-10-17
Diabetologia
Abstract:<h3 class="Heading">Aims/hypothesis</h3><p class="Para">The mechanisms responsible for beta cell compensation in obesity and for beta cell failure in type 2 diabetes are poorly defined. The mRNA levels of several metallothionein (MT) genes are upregulated in islets from individuals with type 2 diabetes, but their role in beta cells is not clear. Here we examined: (1) the temporal changes of islet <em class="EmphasisTypeItalic">Mt1</em> and <em class="EmphasisTypeItalic">Mt2</em> gene expression in mouse models of beta cell compensation and failure; and (2) the role of <em class="EmphasisTypeItalic">Mt1</em> and <em class="EmphasisTypeItalic">Mt2</em> in beta cell function and glucose homeostasis in mice.</p><h3 class="Heading">Methods</h3><p class="Para"><em class="EmphasisTypeItalic">Mt1</em> and <em class="EmphasisTypeItalic">Mt2</em> expression was assessed in islets from: (1) control lean (chow diet-fed) and diet-induced obese (high-fat diet-fed for 6 weeks) mice; (2) mouse models of diabetes (<em class="EmphasisTypeItalic">db/db</em> mice) at 6 weeks old (prediabetes) and 16 weeks old (after diabetes onset) and age-matched <em class="EmphasisTypeItalic">db/+</em> (control) mice; and (3) obese non-diabetic <em class="EmphasisTypeItalic">ob/ob</em> mice (16-week-old) and age-matched <em class="EmphasisTypeItalic">ob/+</em> (control) mice. <em class="EmphasisTypeItalic">MT1E</em>, <em class="EmphasisTypeItalic">MT1X</em> and <em class="EmphasisTypeItalic">MT2A</em> expression was assessed in islets from humans with and without type 2 diabetes. <em class="EmphasisTypeItalic">Mt1-Mt2</em> double-knockout (KO) mice, transgenic mice overexpressing <em class="EmphasisTypeItalic">Mt1</em> under the control of its natural promoter (Tg-<em class="EmphasisTypeItalic">Mt1</em>) and corresponding control mice were also studied. In MIN6 cells, MT1 and MT2 were inhibited by small interfering RNAs. mRNA levels were assessed by real-time RT-PCR, plasma insulin and islet MT levels by ELISA, glucose tolerance by i.p. glucose tolerance tests and overnight fasting-1 h refeeding tests, insulin tolerance by i.p insulin tolerance tests, insulin secretion by RIA, cytosolic free Ca<sup>2+</sup> concentration with Fura-2 leakage resistant (Fura-2 LR), cytosolic free Zn<sup>2+</sup> concentration with Fluozin-3, and NAD(P)H by autofluorescence.</p><h3 class="Heading">Results</h3><p class="Para"><em class="EmphasisTypeItalic">Mt1</em> and <em class="EmphasisTypeItalic">Mt2</em> mRNA levels were reduced in islets of murine models of beta cell compensation, whereas they were increased in diabetic <em class="EmphasisTypeItalic">db/db</em> mice. In humans, <em class="EmphasisTypeItalic">MT1X</em> mRNA levels were significantly upregulated in islets from individuals with type 2 diabetes in comparison with non-diabetic donors, while <em class="EmphasisTypeItalic">MT1E</em> and <em class="EmphasisTypeItalic">MT2A</em> mRNA levels were unchanged. Ex vivo, islet <em class="EmphasisTypeItalic">Mt1</em> and <em class="EmphasisTypeItalic">Mt2</em> mRNA and MT1 and MT2 protein levels were downregulated after culture with glucose at 10–30 mmol/l vs 2–5 mmol/l, in association with increased insulin secretion. In human islets, mRNA levels of <em class="EmphasisTypeItalic">MT1E</em>, <em class="EmphasisTypeItalic">MT1X</em> and <em class="EmphasisTypeItalic">MT2A</em> were downregulated by stimulation with physiological and supraphysiological levels of glucose. In comparison with wild-type (WT) mice, <em class="EmphasisTypeItalic">Mt1-Mt2</em> double-KO mice displayed improved glucose tolerance in association with increased insulin levels and enhanced insulin release from isolated islets. In contrast, isolated islets from Tg-<em class="EmphasisTypeItalic">Mt1</em> mice displayed impaired glucose-stimulated insulin secretion (GSIS). In both <em class="EmphasisTypeItalic">Mt1-Mt2</em> double-KO and Tg-<em class="EmphasisTypeItalic">Mt1</em> models, the changes in GSIS occurred despite similar islet insulin content, rises in cytosolic free Ca<sup>2+</sup> concentration and NAD(P)H levels, or intracellular Zn<sup>2+</sup> concentration vs WT mice. In MIN6 cells, knockdown of MT1 but not MT2 potentiated GSIS, suggesting that <em class="EmphasisTypeItalic">Mt1</em> rather than <em class="EmphasisTypeItalic">Mt2</em> affects beta cell function.</p><h3 class="Heading">Conclusions/interpretation</h3><p class="Para">These findings implicate <em class="EmphasisTypeItalic">Mt1</em> as a negative regulator of insulin secretion. The downregulation of <em class="EmphasisTypeItalic">Mt1</em> is associated with beta cell compensation in obesity, whereas increased <em class="EmphasisTypeItalic">Mt1</em> accompanies beta cell failure and type 2 diabetes.</p>
endocrinology & metabolism